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Abstract Little information is available on the manage-
ment of patients with type 2 diabetes mellitus (DM2) in
regular clinical practice, prior to and at the point of initi-
ating treatment with insulin. The INSTIGATE study pro-
vides a description of the clinical proﬁle of the patient with
DM2 who begins treatment with insulin in both primary
and secondary care. A total of 224 patients who had been
diagnosed with DM2, were not responding to oral treat-
ment, and began receiving insulin were included in the
INSTIGATE study in Spain. Demographic data were col-
lected, as well as data on macro- and microvascular com-
plications of diabetes and comorbidities, past medical
history of diabetes and oral treatment administered, the
clinical severity of diabetes (HbA1c concentration) and
insulin treatment initiated. Mean age of the sample was
65.4 years and 56.7% were men. There were 87% of
patients who had a diagnosis of at least one signiﬁcant
comorbidity, notably hypertension and hyperlipidemia. The
patient proﬁle for metabolic syndrome was met by 75.1%
of the patients. There was a higher incidence of macro-
vascular complications (38.4%) than microvascular com-
plications (16.1%). Prior to insulin initiation, the most
recent mean HbA1c was 9.2%. The majority of patients
had been treated in the last 12 months with sulfonylureas
and/or metformin (69.6 and 57.6%). The most common
treatment prior to insulinization was the co-administration
of two oral antidiabetics (OADs) (37.5%). Patients with
DM2 observed in the study presented with elevated mean
HbA1c and body mass index levels, comorbidities and
complications related to diabetes at the time of insulin
initiation. Changes and adjustments in treatment from
diagnosis of diabetes occur when HbA1c levels are far
above those recommended by the IDF (International Dia-
betes Federation), a factor which could be contributing to
the development of both macrovascular and microvascular
complications in the patient proﬁle described in the study.
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Introduction
Type 2 diabetes mellitus (DM2) is a chronic disease that is
becoming increasingly prevalent inWesternpopulations. At
the beginning of the 1990s, it was estimated that global
prevalence would increase by around 40% over the fol-
lowing 10 years, rising from approximately 150–210 mil-
lion patients [1]. In the absence of adequate glucose control,
patients with DM2 present a higher risk of developing
macrovascular as well as microvascular complications [2].
The high prevalence and incidence of DM2, including the
associated increased morbidity and premature mortality,
make diabetes a major pressure on health resources [3].
In Spain, diabetes mellitus is one of the main causes of
mortality, ranking third place for women [4]. The preva-
lence estimations for DM2 in Spain vary between 4.8% [5]
and 18.7% [6], with an annual incidence between 8.2 [7]
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DOI 10.1007/s00592-009-0158-8and 10.8 cases [8] per 1,000 people. It has been suggested
that more than one-third of people with diabetes in Spain
have not been diagnosed [9].
The International Clinical Guidelines for the manage-
ment of glucose control in patients with type 2 diabetes
published by the International Diabetes Federation (IDF)
recommend implementing changes in the lifestyle of the
patient, followed by different treatment patterns, ranging
from a single oral antidiabetic drug (OAD) to a combina-
tion of oral agents ending up with insulin treatment, always
with the objective of maintaining the HbA1c level under
6.5% [10]. In the observation of daily clinical practice,
insulin initiation for patients is sometimes delayed due to
the potential risk of hypoglycemia, the need to educate
patients on the use of insulin, the need to increase glucose
control and concern over weight gain [11].
Studies were conducted in the past that describe the
pattern of oral antidiabetic and insulin use. These provide
data on the level of glucose control achieved with each of
these treatments, individually or combined, at different
stages of the disease, the development of complications
associated with DM2, the duration of therapy for each
deﬁned treatment pattern and clinical variables at the time
the medication was changed [12–15].
However, the information provided by these studies
needs to be updated, since in recent years, signiﬁcant
innovations have appeared within drug treatment options
for DM2. In addition, the clinical guidelines for glucose
control in type 2 diabetes published by the IDF have
recently been reviewed, updating both the recommenda-
tions on glucose [10] and metabolic control [16], and the
deﬁnition of the proﬁle of patients with metabolic syn-
drome [17]. Therefore, describing treatment patterns in
clinical practice and evaluating the proportion of patients
who comply with the recommendations of these interna-
tional guidelines appear to be of major importance in the
management of patients with DM2, allowing the imple-
mentation of initiatives that improve compliance and thus
the clinical situation of the patients.
The present study describes the clinical proﬁle of the
DM2 patient who begins insulin treatment in primary and/or
secondary care.
Methods
The present work was conducted with baseline data, relat-
ing to a Spanish sample in the European non-interventional,
multicenter, prospective, observational INSTIGATE study,
in which we provide a description of the proﬁle of the DM2
patient who begins insulin treatment in primary and/or
secondary care in Spain. The study was designed to deter-
mine the direct costs associated with the ﬁrst 24 months of
insulin treatment in patients with DM2 and to describe the
utilization of resources, the quality of metabolic control and
the associated clinical results. This study included patients
with DM2 who began treatment with insulin because they
did not have acceptable glucose control levels according to
clinical judgement and who granted their informed consent.
In addition to the baseline data published for the whole
European sample [18], the present paper allows a closer
look at the Spanish patients within the study, especially in
relation to comorbidities at the time of insulin initiation, and
treatment patterns before and at the point of initiation of
insulin therapy and provides the opportunity to put the data
in context within a Spanish environment.
Sites were selected so that the geographic distribution
and investigator type (general practitioner or specialist)
were representative of the physician population treating
patients with type 2 diabetes both up to and through the
insulin initiation process. Specialist secondary care centers
that did not care for the entire spectrum of patients with
diabetic were not included, as these patients were less
likely to be representative of the usual patient initiating
insulin in Spain.
The participating investigators identiﬁed patients with
DM2 who (1) began treatment with insulin at that visit to
the doctor’s ofﬁce or (2) were promptly sent by the primary
care physician to a specialist so that insulin treatment could
be initiated, continuing their clinical follow-up at the pri-
mary care ofﬁce.
At the initial visit of this study, the following data were
collected:
1. Demographic and anthropometric characteristics of
the patient: age, sex, ethnic identity, smoking status,
height, weight and waist circumference.
2. Presence of medical complications: coronary disease,
stroke, occlusive peripheral artery disease, congestive
heart failure, diabetic retinopathy, diabetic nephropa-
thy, diabetic neuropathy, amputation of any limb,
hypertension, hyperlipidemia, depression, cancer and
other comorbidities.
3. Past medical history of diabetes: date of diagnosis,
treatment patterns prior to insulin initiation (duration
and type of therapy) and OAD drugs (generic name,
dose, frequency, start date and end date and the reason
for discontinuation) taken during the 12 months prior
to insulin initiation.
4. Clinical severity: based on HbA1c levels, lipid proﬁle,
fasting plasma glucose and blood pressure.
5. Insulin treatment: description of insulin treatment
initiated at the beginning of the study.
As INSTIGATE is an observational study, results were
obtained from the medical records and supported by the
clinical judgement of the investigators. All data were
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123provided as they were generated in usual care and no
additional visits, tests or interventions were required as part
of the study protocol.
Data on HbA1c (%), lipids (HDL-cholesterol LDL-
cholesterol and triglycerides) and blood pressure of each
eligible patient were compared with the levels recom-
mended by the IDF to determine what proportion of the
Spanish population in the study was achieving target. The
following are the current recommended targets:
• HbA1c\6.5%
• Lipids: HDLc[39 mg/dL, LDLc\95 mg/dL and
triglycerides\200 mg/dL
• Blood pressure\130/80 mmHg [16].
Data on waist circumference, triglyceride level, HDLc,
blood pressure and fasting blood glucose levels were used to
evaluate the proportion of patients from the Spanish sample
whometthecriteriaforthediagnosisofmetabolicsyndrome
according to the guidelines published by the IDF [17].
Forapatienttobediagnosedwithmetabolicsyndrome,in
accordance with the deﬁnition by the IDF, European men
must have a waist circumference C94 cm and European
women C80 cm and, at least two of the following factors:
1. An elevated triglyceride level: C150 mg/dL or a
treatment speciﬁc to this lipid abnormality.
2. ReducedHDLclevel:\40 mg/dLinmenand\50 mg/dL
in women or a speciﬁc treatment for this lipid
abnormality.
3. Raised systolic blood pressure C 130 mmHg or dia-
stolic blood pressure C85 mmHg or treatment for
previously diagnosed hypertension.
4. Raised blood glucose level: fasting blood glu-
cose C 100 mg/dL or previously diagnosed with DM2.
Statistical analysis
The variables from the study on the demographic, clinical
and treatment characteristics were analyzed using
descriptive statistics: mean, standard deviation, median,
minimum and maximum for quantitative variables and
relative and absolute frequencies for qualitative variables.
If not stated otherwise, percentages are based on the
number of eligible patients. All analyses were conducted
using SAS software version 8.2.
Results
The results refer to the 224 patients included in the
INSTIGATE study in Spain, by 24 investigators (9
Table 1 Patient characteristics
Parameter Mean (SD) n
Weight (kg) 77.72 (15.67) 224
Body mass index (kg/m
2) 29.54 (5. 50) 224
Abdominal perimeter (cm) 99.9 (16.57) 224
Men (cm) 101.9 (15.32) 127
Women (cm) 97.3 (17.81) 97
Systolic blood pressure (mmHg) 137.1 (18.35) 216
Diastolic blood pressure (mmHg) 78.6 (10.79) 216
HDLc (mg/dL) 49.30 (15.07) 209
LDLc (mg/dL) 108.04 (37.28) 208
Triglycerides (mg/dL) 173.7 (98.55) 215
HbA1c at diagnosis (%) 8.23 (1.88) 49
Time since ﬁrst diagnosed (years) 10.26 (7.14) 220
Current smokers [n (%)] 22 (9.8%) 224
The results are presented as mean results (standard deviation) except
for the percentage of smokers
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Fig. 1 Evaluation of the
clinical severity of diabetes
through HbA1c measurement
prior to insulin initiation
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123endocrinologists, 8 internal medicine specialists and 7
primary care physicians) at the point of insulin initiation.
The majority of the patients were men (56.7%), Cau-
casian (97.8%), with a mean age of 65.4 (SD = 12.1)
years, with women being older, 67.2 (11.5) than men,
64.1(12.5). The principal patient characteristics are pre-
sented in Table 1.
Of the total patient population, 36% were overweight
(25 B BMI\30) and 43.3% were obese (BMI C 30).
Women presented a more elevated mean BMI value than
men [30.56 (6.36) vs. 28.77 (4.63) kg/m
2, respectively].
Clinical severity was evaluated through HbA1c measure-
ment. Mean HbA1c at diagnosis of the disease and
12 months prior to insulinization were much higher than
the glucose control targets recommended by the IDF,
reaching a value of 9.2% prior to insulin initiation (Fig. 1).
There were a few patients (n = 9) who presented HbA1c
values below 6.5% at insulin initiation who may have
started this treatment due to other clinical factors or
comorbidities where clinical judgment advised tight glu-
cose control. Patients with HbA1c[8.0% versus patients
with 6.5%\HbA1c B 8.0% had higher rates of chronic
complications (88.0 vs. 82.4%, respectively). In addition,
patients who had at least one macrovascular complication
had higher mean values of HbA1c % (9.29%) than those
who did not (8.94%).
Figure 2 presents the percentage of eligible patients who
meet the therapeutic goals established by the IDF, with
respect to lipid values (LDLc, HDLc and triglycerides),
blood pressure, and HbA1c concentration and the criteria
for diagnosis of metabolic syndrome.
For the diagnosis of metabolic syndrome at baseline, a
smaller sample (n = 209) than that included in the study
was evaluated, due to the absence of at least one data
element necessary for this evaluation for some patients.
There were 75.1% of evaluable patients who met the
patient proﬁle for metabolic syndrome, 95.7% who
presented an unacceptable HbA1c concentration level
([6.5%) and 63.9% who presented an LDLc level higher
than the clinical recommendation (95 mg/dL).
The majority of the population studied (87%) presented
with at least one signiﬁcant comorbidity, 38.4% had mac-
rovascular complications and 16.1% microvascular com-
plications (Table 2). Coronary disease was the most
frequent macrovascular complication followed by conges-
tive heart failure; with respect to microvascular compli-
cations, diabetic nephropathy was more frequent than
retinopathy or neuropathy in the sample studied.
In regard to oral treatment during the 12 months prior to
insulin initiation, the majority of the patients had received
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Table 2 Comorbidity incidence in patients at the time of insulin
initiation (n = 224)
Comorbidity n (%) of patients
with comorbidity
Macrovascular complications (at least 1) 86 (38.4)
Coronary disease 49 (21.9)
Stroke 18 (8.0)
Transient ischemic attack 10 (4.5)
Peripheral occlusive arterial disease 13 (5.8)
Congestive heart failure 24 (10.7)
Amputation 2 (0.9)
Microvascular complications (at least 1) 36 (16.1)
Diabetic retinopathy 15 (6.7)
Diabetic nephropathy 23 (10.3)
Diabetic neuropathy 9 (4.0)
Other comorbidities (at least 1) 182 (81.3)
Hypertension 137 (61.2)
Hyperlipidemia 111 (49.6)
Depression 29 (12.9)
Cancer 12 (5.4)
Others 48 (21.4)
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123sulfonylureas (156 patients; 69.6%) and/or metformin (129
patients; 57.6%) and to a lesser degree, thiazolidinediones
(33 patients; 14.7%), alpha-glucosidase inhibitors (29
patients; 12.9%), meglitinides (36 patients; 16.1%) and
other drugs (6 patients; 2.7%).
In the period between being diagnosed with DM2 and
insulin initiation, 39.5% of the patients had modiﬁed their
treatment patterns progressing from 1 to 2 OADs prior to
insulin initiation, 17.9% had received only single OAD
therapy prior to insulin, 11.2% had progressed from 1 to 2
then 3 OADs, 8.5% had received only dual therapy with
OADs, 9.4% did not know the antidiabetic treatment his-
tory and 6.3% of the patients had not been treated with
OADs. Figure 3 presents the different patterns followed in
One oral antidiabetic 
172 patients 
HbA1c (SD) at treatment initiation: 
7.9% (1.45) 
Treatment duration (SD) with one 
oral antidiabetic: 5.5 years (5.68) 
113 patients 
HbA1c (SD) when treatment was changed 8.5% (1.38) 
Two oral antidiabetics 
160 patients 
HbA1c (SD) at treatment initiation: 
8.5% (1.53) 
Treatment duration (SD) with two oral 
antidiabetics: 3.9 years (3.02) 
32 patients 
HbA1c (SD) when treatment was changed 8.6% (1.57) 
Three oral antidiabetics 
47 patients 
HbA1c (SD)  at treatment initiation:  8.6% (1.59) 
Treatment duration (SD) with three 
oral antidiabetics: 2.2 years (1.88)
Four oral antidiabetics 
1 patient 
HbA1c (SD) at treatment initiation: (n=1) 8.8% 
Treatment duration (SD) with four 
oral antidiabetics: (n=1) 0.3 years
40 patients 
HbA1c (SD) when 
treatment was changed 
8.8% (1.68) 
107 patients 
HbA1c (SD) when 
treatment was changed 
9.4% (1.78) 
39 patients 
HbA1c (SD) when 
treatment was changed 
9.5% (1.17) 
1 patient 
HbA1c (SD) when 
treatment was changed 
8.8% 
Insulin  224 patients
HbA1c (SD) prior to treatment (n=210) 9.2% (1.62)
19 patients
Unknown 
21 patients
8 patients
Fig. 3 Different treatment patterns for DM2 before insulinization
Acta Diabetol (2010) 47 (Suppl 1):S169–S175 S173
123the treatment prior to insulin initiation, demonstrating the
mean HbA1c at the time of change in therapy and the
duration of treatment on each therapy.
Table 3 describes the insulin regimen initially pre-
scribed for the subjects studied. The most common insulin
treatment was a basal insulin only, which was received by
60.3% of the subjects.
Discussion
The results of the current study suggest patients with DM2
initiating treatment with insulin in Spain are on average
aged 65, have had a diagnosis of DM2 for around 10 years
and are likely to be overweight or obese. Figure 1 indicates
that the majority of patients ([75%) had HbA1c values
higher than those recommended by the IDF during the year
prior to initiation of insulin. These results are supported by
several studies [15, 19, 20], which have evidenced that only
a small proportion of patients with diabetes achieve ther-
apeutic objectives in relation to metabolic control, in spite
of a number of publications in recent years manifesting the
importance of attaining a good control to prevent or delay
the development of complications associated with DM2
[12, 13, 16].
The majority of evaluable patients from the INSTI-
GATE study met the criteria for the diagnosis of metabolic
syndrome. These patients are estimated to present twice the
risk of mortality and three times the risk of cardiovascular
disease, compared to healthy individuals [21].
Glucose control strategies and recommendations on
HbA1c targets are currently under discussion since ﬁndings
from recently published trials, such as ACCORD,
ADVANCE and VADT have not demonstrated a signiﬁ-
cant reduction in cardiovascular disease with intensive
glycemic control [22, 23]. However, conversely, the
10-year follow-up data of the UKPDS study did show a
reduction in myocardial infarction and all-mortality cause
associated to intensive glucose lowering [24].
With regard to treatment patterns followed by patients in
the INSTIGATE study, the changes in treatment occurred
when the mean HbA1c value was at least 8.5%, which is
well above the levels recommended by the IDF guidelines
[10] and the consensus treatment algorithm developed by
the ADA (American Diabetes Association) in collaboration
with the EASD (European Association for the Study of
Diabetes) [25]. In addition, at insulin initiation, mean
HbA1c was very high (9.15%). Mean HbA1c was lower for
patients with one oral antidiabetic than for patients with
two or more oral antidiabetics as their immediate previous
treatment (Fig. 3).
A limitation of the INSTIGATE study is that although
patients were included in a prospective manner from the
time of insulin initiation, part of the data collection was
retrospective, and obtained from the clinical history. Due to
the fact that it was an observational study, all results were
provided as they were generated in usual care, and there-
fore the values of HbA1c% and other lab results were not
standardized. Statistical analysis comparing patients from
various settings were not carried out since it was not a
speciﬁed objective of the study to look at possible differ-
ences between patients being treated in primary and sec-
ondary care. However, this could be an interesting analysis
to consider for future studies. Finally, it is possible that a
very small number of patients included in the study could
have had undiagnosed LADA (Latent Autoimmune Dia-
betes of the Adult) with an incorrect diagnosis of type 2
diabetes. Given the observational nature of the study, no
additional tests could have been run to conﬁrm diabetes
type.
The baseline data for the Spanish sample of the
INSTIGATE study demonstrate that initiation of insulin
therapy in patients with DM2 occurs only after patients
have had poor glycemic control for a sustained period of
time (Fig. 1). Due to the high prevalence of cardiovascular
risk factors and comorbidities related to diabetes, we can
consider the studied patients are at high risk of cardio-
vascular disease and associated mortality. It appears,
Table 3 Treatment patterns of insulin initiation
Initial administration of insulin n Percentage
of patients
Mean number
of injections
Mean daily
dose (IU)
Mean daily dose
(IU)/kg of weight
Basal 135 60.3 1.1 16.9 0.23
Pre-established mixtures 42 18.8 2.0 29.9 0.37
Only rapid 21 9.4 2.5 23.6 0.34
Basal/bolus 4 1.8 2.5 24.0 0.36
Other 2 0.9 1.0 15.33 0.21
Basal and mixed 1 0.4 2.0 24.0 –
Unknown 19 8.5 – – –
Total 224 100 – 20.0 –
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123therefore, that more needs to be done to encourage earlier
intervention to intensify therapy, in accordance with cur-
rent recommendations for the treatment of DM2, with the
ﬁnal objective of achieving more effective glucose control,
and ultimately avoiding or delaying the development of
complications associated with diabetes, a cause of high
morbidity and mortality in patients with DM2.
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